Cellectar Biosciences Q3 EPS $(1.41) Beats $(2.53) Estimate

Cellectar Biosciences (NASDAQ: CLRB) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of $(2.53) by 44.2 percent. This is a 88.25 percent increase over losses of $(12.00) per share from the same period last year.